Načítá se...
Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer
Recent clinical trials demonstrating the efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of BRCA1-deficient breast cancer have provided support for the 'synthetic lethal' concept of targeted cancer therapeutics. A new study provides further preclinical validatio...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2790845/ https://ncbi.nlm.nih.gov/pubmed/19804613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2362 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|